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with XPD312 AspAsp (36.4 m) than for 27 p with Asn variants (9.8 
m) (P=0.009); MS in this group of younger p was 45.4 m for AspAsp 
vs 15.8 m for Asn (P=0.04). No other signiﬁcant correlation between 
SNPs and survival was observed (Table). 
Conclusions: Interaction between SNPs, age and risk of lung cancer 
has previously been described. XPD312 AspAsp in p <59 y predicts 
longer survival in stage IIIA (N2) and IIIB NSCLC treated with neoad-
juvant chemotherapy.
  EFS   MS  
 N m (95% CI) P N m (95% CI) P
XPD 751   0.13   0.15
LysLys 45 13.22 (3.49-22.95)  45 32.14 (5.08-59.20)  
LysGln& 
GlnGln 64 8.82 (6.11-11.52)  64 14.90 (10.39- 19.41)  
XPD312   0.03   0.05
AspAsp 55 13.98 (4.79 - 23.17)  55 32.14 (7.58-56.70)  
AspAsn& 
AsnAsn 54 7.34 (4.53-10.14)  54 12.04 (6.09-17.99)  
RRM1-37   0.87   0.53
CC 59 9.11 (6.03-12.09)  59 14.97 (4.61-25.32)  
CA & AA 49 10.79 (8.22- 13.36)  49 16.84 (1.50-32.18)  
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Background: BIBF 1120 is an orally available, highly potent triple 
angiokinase inhibitor (VEGFRs, PDGFRs, FGFRs) that inhibits tumor 
growth through mechanisms suppressing tumor neovascularization. 
This Phase I, open-label dose escalation study investigated the combi-
nation of BIBF 1120 together with carboplatin and paclitaxel in previ-
ously untreated patients with advanced stage (IIIB/IV) NSCLC. The 
primary objectives of this trial were to determine the safety, tolerability, 
and maximum tolerated dose (MTD) of BIBF 1120 in combination 
with carboplatin and paclitaxel.
Methods: Untreated patients with advanced stage NSCLC, PS 0-1 
were eligible for this trial. Patients with squamous cell histology were 
eligible, but patients with cavitary or necrotic tumors or those with ra-
diologic evidence of great vessel invasion were excluded. The trial was 
an open label, dose escalation design with BIBF 1120 (starting dose 50 
mg bid) taken on days 2-21, combined with carboplatin (AUC=6) and 
paclitaxel (200 mg/m2) on day 1 of each 21 day cycle. Patients could 
be treated for a minimum of four and a maximum of six cycles of com-
bination therapy, with an option for BIBF 1120 monotherapy following 
completion of planned combination therapy. BIBF 1120 was escalated 
at doses of 50 mg per cohort until the MTD dose was determined. MTD 
was deﬁned as the dose of BIBF 1120 that at which two or more out of 
six patients experienced dose limiting toxicity (DLT) in the ﬁrst treat-
ment cycle. Tumor assessments were performed at screening and after 
every second treatment cycle according to RECIST.
Results: Twenty-ﬁve patients (18 females and 7 males) in total and 14 
at the MTD were treated in this study. The MTD dose of BIBF 1120 
was determined to be 200 mg bid in combination with carboplatin and 
paclitaxel and the combination of BIBF 1120 with this doublet was 
well tolerated. Five DLT events occurred in the ﬁrst treatment cycle 
for all doses including elevations in liver enzymes (2/5), thrombocy-
topenia (1/5), abdominal pain (1/5), and rash (1/5) and resolved after 
discontinuation of study medication. Ten patients received BIBF 1120 
monotherapy after completing their planned combination therapy (2 to 
6 additional cycles). Best responses by RECIST (17 patients evaluable 
for response) include 7 partial responses (PR) and 10 patients with 
stable disease (SD). 
Conclusions: The combination of BIBF 1120 together with carboplatin 
and paclitaxel in previously untreated patients with advanced NSCLC 
as shown to be safe and well-tolerated in this study. The MTD dose of 
BIBF 1120 was 200 mg bid when given with carboplatin and paclitaxel 
every three weeks. Initial signs of clinical efﬁcacy were observed in the 
small number of patients treated in this trial.
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Background: Erlotinib (Tarceva) is an orally active, selective EGFR 
inhibitor. In a large, phase III trial (BR.21) second- or third-line 
erlotinib monotherapy (150mg/day) signiﬁcantly prolonged survival in 
patients with advanced non-small-cell lung cancer (NSCLC). The erlo-
tinib expanded access programme ( TRUST ) was designed to evaluate 
the safety and efﬁcacy of erlotinib and has enabled more than 11500 
patients worldwide to receive erlotinb treatment. This paper reports the 
preliminary outcome of erlotinib treatment in Chinese patients who en-
rolled into the EAP at Cancer Institute/ Hospital, Chinese Academy of 
Medical Sciences(CAMS) & Peking Union Medical College(PUMC).
Methods: Patients with stage IIIB / IV NSCLC, with performance 
status from 0 to 3, were eligible if they had received one or two prior 
platinum-based chemotherapy regimens. Patients received oral erlotinib 
(150mg/day) until unacceptable toxicity or disease progression.Dose 
interruption or dose reduction (to 100mg then 50mg) was permitted for 
treatment-related AEs. 
Results: The median age of the 45 patients who underwent ran-
domization was 54.9(28-74 ) years. Baseline characteristics (% 
of patients) were:male/female:69/31;ECOG performance status 
0/1/2/3:18/58/15/9;stage IIIB / IV:80/20;non-smoker/former or 
current smoker:69/31;ademocarcinoma/squamous cell carcinoma 
67/20;erlotinib as second-line/third-line treatment: 69/31.Safety and 
efﬁcacy data were available for 42 patients. Erlotinib-ralated ad-
verse events (AEs) were generally mild (grade1 and 2 assessed using 
CTCAE 3.0) and reversible. The most frequent AEs were acneform 
rash (76%),diarrhea(55%),and elevated indirect serum bilirubin 
levels(50%). Grade 3 AE was elevation of alanine aminotransferase 
(ALT,5%).No patients withdrew because of erlotinib-related event. One 
patient had a dose reduction to 100 mg, due to abnormal hepatic func-
